João Paulo Maia‐de‐Oliveira

Biographic Data

ID7957442
NAMEJoão Paulo Maia‐de‐Oliveira
GIVEN NAMESJoão Paulo
FAMILY NAMEMaia‐de‐Oliveira
SIGNATUREDE OLIVEIRA J P M
AFFILIATIONSHospital Universitário Onofre Lopes
ORCID0000-0002-7637-2498
VERIFIEDYes
TOTAL WORKS6
TOTAL CITATIONS0
AUTHOR COUNT6
EDITOR COUNT0
FIRST PUBLICATION YEAR2015
LATEST PUBLICATION YEAR2023
H-INDEX0

  • Psychophysiological responses to group cognitive-behavioral therapy in depressive patients

    Open AccessYves Martins Varela, Raíssa Nóbrega de Almeida et al.ARTICLECurrent Psychology2023

  • Moderators of ayahuasca’s biological antidepressant action

    Open AccessGeovan Menezes de Sousa, Vagner Deuel De O Tavares et al.ARTICLEFrontiers in Psychiatry2022

    In summary, some specific emotional and physiological parameters during experimental ayahuasca session were revealed as critical moderators of the improvement of major depression biomarkers, mainly BDNF and SC two days after ayahuasca intake. These findings contribute to paving the way for future studies investigating the biological antidepressant response to psychedelic therapy

  • Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial

    Open AccessFernanda Palhano-Fontes, Dayanna Barreto et al.ARTICLEPsychological Medicine2019

    Background Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods To test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either ayahuasca or placebo. We assessed changes in depression severity…

  • Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls

    Open AccessAna Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida et al.ARTICLEFrontiers in Psychiatry2018

    Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cort…

  • Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study

    Rafael Faria Sanches, Flávia de Lima Osório et al.ARTICLEJournal of Clinical Psychopharmacol…2016

    Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on reg…

  • Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report

    Open AccessFlávia de Lima Osório, Rafael Faria Sanches et al.ARTICLEBrazilian Journal of Psychiatry2015

    OBJECTIVES: Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions. This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode. METHODS: Open-label trial conducted in an inpatient psychiatric unit. RESULTS: Statistically significant re…